Nebivolol/valsartan

Drug Profile

Nebivolol/valsartan

Alternative Names: Byvalson; Valsartan/nebivolol

Latest Information Update: 13 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Forest Laboratories
  • Developer Allergan
  • Class Antihypertensives; Benzopyrans; Ethanolamines; Ischaemic heart disorder therapies; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Essential hypertension

Most Recent Events

  • 07 Jun 2016 Registered for Essential hypertension in USA (PO) (First global approval)
  • 07 Jun 2016 The US approved label of nebivolol/valsartan tablets carries a black box warning
  • 22 Feb 2016 Allergan announces intention to submit NDA to US FDA in the first half of 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top